<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39408868</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>16</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>19</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>30</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Insights into the Replication Kinetics Profiles of Malaysian SARS-CoV-2 Variant Alpha, Beta, Delta, and Omicron in Vero E6 Cell Line.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">10541</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms251910541</ELocationID><Abstract><AbstractText>Comprehending the replication kinetics of SARS-CoV-2 variants helps explain why certain variants spread more easily, are more contagious, and pose a significant health menace to global populations. The replication kinetics of the Malaysian isolates of Alpha, Beta, Delta, and Omicron variants were studied in the Vero E6 cell line. Their replication kinetics were determined using the plaque assay, quantitative real-time PCR (qRT-PCR), and the viral growth curve. The Beta variant exhibited the highest replication rate at 24 h post-infection (h.p.i), as evidenced by the highest viral titers and lowest viral RNA multiplication threshold. The plaque phenotypes also varied among the variants, in which the Beta and Omicron variants formed the largest and smallest plaques, respectively. All studied variants showed strong cytopathic effects after 48 h.p.i. The whole-genome sequencing highlighted cell-culture adaptation, where the Beta, Delta, and Omicron variants acquired mutations at the multibasic cleavage site after three cycles of passaging. The findings suggest a strong link between the replication rates and their respective transmissibility and pathogenicity. This is essential in predicting the impacts of the upcoming variants on the local and global populations and is useful in designing preventive measures to curb virus outbreaks.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mohd Zawawi</LastName><ForeName>Zarina</ForeName><Initials>Z</Initials><Identifier Source="ORCID">0000-0001-5727-7359</Identifier><AffiliationInfo><Affiliation>Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam 40170, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalyanasundram</LastName><ForeName>Jeevanathan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0004-1555-1507</Identifier><AffiliationInfo><Affiliation>Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam 40170, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohd Zain</LastName><ForeName>Rozainanee</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Virology Unit, Infectious Disease Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam 40170, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mat Ripen</LastName><ForeName>Adiratna</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5690-8008</Identifier><AffiliationInfo><Affiliation>Cancer Research Centre, Institute for Medical Research, National Institutes of Health, Ministry of Health, Shah Alam 40170, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basri</LastName><ForeName>Dayang Fredalina</ForeName><Initials>DF</Initials><AffiliationInfo><Affiliation>Center for Diagnostic, Therapeutic and Investigative Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yap</LastName><ForeName>Wei Boon</ForeName><Initials>WB</Initials><Identifier Source="ORCID">0000-0003-2449-8395</Identifier><AffiliationInfo><Affiliation>Center for Toxicology and Health Risk Studies, Faculty of Health Sciences, Universiti Kebangsaan Malaysia, Kuala Lumpur 50300, Malaysia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>One Health UKM, Universiti Kebangsaan Malaysia, Bangi 43600, Malaysia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>FRGS/1/2021/STG03/UKM/02/2</GrantID><Agency>Malaysia Ministry of Higher Education</Agency><Country /></Grant><Grant><GrantID>NMRR ID-22-01257-WCO</GrantID><Agency>Malaysia Ministry of Health</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002522" MajorTopicYN="N">Chlorocebus aethiops</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName><QualifierName UI="Q000472" MajorTopicYN="N">pathogenicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014779" MajorTopicYN="Y">Virus Replication</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014709" MajorTopicYN="N">Vero Cells</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009154" MajorTopicYN="N">Mutation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007700" MajorTopicYN="N">Kinetics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008296" MajorTopicYN="N" Type="Geographic">Malaysia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016679" MajorTopicYN="N">Genome, Viral</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">cell culture adaptation</Keyword><Keyword MajorTopicYN="N">infectivity</Keyword><Keyword MajorTopicYN="N">mutations</Keyword><Keyword MajorTopicYN="N">replication kinetics</Keyword><Keyword MajorTopicYN="N">variants</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>16</Day><Hour>1</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39408868</ArticleId><ArticleId IdType="pmc">PMC11477365</ArticleId><ArticleId IdType="doi">10.3390/ijms251910541</ArticleId><ArticleId IdType="pii">ijms251910541</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rahimi G., Rahimi B., Panahi M., Abkhiz S., Saraygord-Afshari N., Milani M., Alizadeh E. An overview of Betacoronaviruses-associated severe respiratory syndromes, focusing on sex-type-specific immune responses. Int. Immunopharmacol. 2021;92:107365. doi: 10.1016/j.intimp.2021.107365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2021.107365</ArticleId><ArticleId IdType="pmc">PMC7797024</ArticleId><ArticleId IdType="pubmed">33440306</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu C.Y., Wong S.Y., Liew N.W.C., Joseph N., Zakaria Z., Nurulfiza I., Soe H.J., Kairon R., Amin-Nordin S., Chee H.Y. Whole genome sequencing analysis of SARS-CoV-2 from Malaysia: From alpha to Omicron. Front. Med. 2022;9:1001022. doi: 10.3389/fmed.2022.1001022.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.1001022</ArticleId><ArticleId IdType="pmc">PMC9537942</ArticleId><ArticleId IdType="pubmed">36213636</ArticleId></ArticleIdList></Reference><Reference><Citation>Azami N.A.M., Perera D., Thayan R., AbuBakar S., Sam I.C., Salleh M.Z., Isa M.N.M., Ab Mutalib N.S., Aik W.K., Suppiah J., et al. Malaysia COVID-19 Genomics Surveillance Consortium. SARS-CoV-2 genomic surveillance in Malaysia: Displacement of B.1.617.2 with AY lineages as the dominant Delta variants and the introduction of Omicron during the fourth epidemic wave. Int. J. Infect. Dis. 2022;125:216–226. doi: 10.1016/j.ijid.2022.10.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.10.044</ArticleId><ArticleId IdType="pmc">PMC9632236</ArticleId><ArticleId IdType="pubmed">36336246</ArticleId></ArticleIdList></Reference><Reference><Citation>Amicone M., Borges V., Alves M.J., Isidro J., Zé-Zé L., Duarte S., Vieira L., Guiomar R., Gomes J.P., Gordo I. Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution. Evol. Med. Public Health. 2022;10:142–155. doi: 10.1093/emph/eoac010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emph/eoac010</ArticleId><ArticleId IdType="pmc">PMC8996265</ArticleId><ArticleId IdType="pubmed">35419205</ArticleId></ArticleIdList></Reference><Reference><Citation>Peacock T.P., Penrice-Randal R., Hiscox J.A., Barclay W.S. SARS-CoV-2 one year on: Evidence for ongoing viral adaptation. J. Gen. Virol. 2021;102:001584. doi: 10.1099/jgv.0.001584.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/jgv.0.001584</ArticleId><ArticleId IdType="pmc">PMC8290271</ArticleId><ArticleId IdType="pubmed">33855951</ArticleId></ArticleIdList></Reference><Reference><Citation>Luan B., Wang H., Huynh T. Enhanced binding of the N501Y-mutated SARS-CoV-2 spike protein to the human ACE2 receptor: Insights from molecular dynamics simulations. FEBS Lett. 2021;595:1454–1461. doi: 10.1002/1873-3468.14076.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1873-3468.14076</ArticleId><ArticleId IdType="pmc">PMC8250610</ArticleId><ArticleId IdType="pubmed">33728680</ArticleId></ArticleIdList></Reference><Reference><Citation>Tegally H., Wilkinson E., Giovanetti M., Iranzadeh A., Fonseca V., Giandhari J., Doolabh D., Pillay S., San E.J., Msomi N., et al. Detection of a SARS-CoV-2 variant of concern in South Africa. Nature. 2021;592:438–443. doi: 10.1038/s41586-021-03402-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03402-9</ArticleId><ArticleId IdType="pubmed">33690265</ArticleId></ArticleIdList></Reference><Reference><Citation>Focosi D., Maggi F. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based Covid-19 therapeutics and vaccines. Rev. Med. Virol. 2021;31:e2231. doi: 10.1002/rmv.2231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2231</ArticleId><ArticleId IdType="pmc">PMC8250244</ArticleId><ArticleId IdType="pubmed">33724631</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhawan M., Sharma A., Priyanka, Thakur N., Rajkhowa T.K., Choudhary O.P. Delta variant (B.1.617.2) of SARS-CoV-2: Mutations, impact, challenges and possible solutions. Hum. Vaccines Immunother. 2022;18:2068883. doi: 10.1080/21645515.2022.2068883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2022.2068883</ArticleId><ArticleId IdType="pmc">PMC9359381</ArticleId><ArticleId IdType="pubmed">35507895</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan Y., Li X., Zhang L., Wan S., Zhang L., Zhou F. SARS-CoV-2 Omicron variant: Recent progress and future perspectives. Signal Transduct. Target. Ther. 2022;7:141. doi: 10.1038/s41392-022-00997-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00997-x</ArticleId><ArticleId IdType="pmc">PMC9047469</ArticleId><ArticleId IdType="pubmed">35484110</ArticleId></ArticleIdList></Reference><Reference><Citation>Hatta Y., Hershberger K., Shinya K., Proll S.C., Dubielzig R.R., Hatta M., Katze M.G., Kawaoka Y., Suresh M. Viral replication rate regulates clinical outcome and CD8 T cell responses during highly pathogenic H5N1 influenza virus infection in mice. PLoS Pathog. 2010;6:e1001139. doi: 10.1371/journal.ppat.1001139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1001139</ArticleId><ArticleId IdType="pmc">PMC2951384</ArticleId><ArticleId IdType="pubmed">20949022</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee L.Y., Rozmanowski S., Pang M., Charlett A., Anderson C., Hughes G.J., Barnard M., Peto L., Vipond R., Sienkiewicz A., et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectivity by viral load, S gene variants and demographic factors, and the utility of lateral flow devices to prevent transmission. Clin. Infect. Dis. 2022;74:407–415. doi: 10.1093/cid/ciab421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab421</ArticleId><ArticleId IdType="pmc">PMC8136027</ArticleId><ArticleId IdType="pubmed">33972994</ArticleId></ArticleIdList></Reference><Reference><Citation>Banerjee A., Nasir J.A., Budylowski P., Yip L., Aftanas P., Christie N., Ghalami A., Baid K., Raphenya A.R., Hirota J.A., et al. Isolation, sequence, infectivity, and replication kinetics of severe acute respiratory syndrome coronavirus 2. Emerg. Infect. Dis. 2020;26:2054. doi: 10.3201/eid2609.201495.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2609.201495</ArticleId><ArticleId IdType="pmc">PMC7454076</ArticleId><ArticleId IdType="pubmed">32558639</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Liu M.-Q., Luo Y., Jiang R.-D., Si H.-R., Zhu Y., Li B., Shen X.-R., Lin H.-F., Zhao K., et al. Genetic mutation of SARS-CoV-2 during consecutive passages in permissive cells. Virol. Sin. 2021;36:1073–1076. doi: 10.1007/s12250-021-00384-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12250-021-00384-w</ArticleId><ArticleId IdType="pmc">PMC8071843</ArticleId><ArticleId IdType="pubmed">33900543</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson C.B., Farzan M., Chen B., Choe H. Mechanisms of SARS-CoV-2 entry into cells. Nat. Rev. Mol. Cell Biol. 2022;23:3–20. doi: 10.1038/s41580-021-00418-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41580-021-00418-x</ArticleId><ArticleId IdType="pmc">PMC8491763</ArticleId><ArticleId IdType="pubmed">34611326</ArticleId></ArticleIdList></Reference><Reference><Citation>Emeny J.M., Morgan M.J. Regulation of the interferon system: Evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 1979;43:247–252. doi: 10.1099/0022-1317-43-1-247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1099/0022-1317-43-1-247</ArticleId><ArticleId IdType="pubmed">113494</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosli S.N.Z., Dimeng S.R., Shamsuddin F., Mohd Ali M.R., Muhamad Hendri N.A., Suppiah J., Mohd Zain R., Thayan R., Ahmad N. Vero CCL-81 and Calu-3 cell lines as alternative hosts for isolation and propagation of SARS-CoV-2 isolated in Malaysia. Biomedicines. 2023;11:1658. doi: 10.3390/biomedicines11061658.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11061658</ArticleId><ArticleId IdType="pmc">PMC10295990</ArticleId><ArticleId IdType="pubmed">37371753</ArticleId></ArticleIdList></Reference><Reference><Citation>Mautner L., Hoyos M., Dangel A., Berger C., Ehrhardt A., Baiker A. Replication kinetics and infectivity of SARS-CoV-2 variants of concern in common cell culture models. Virol. J. 2022;19:76. doi: 10.1186/s12985-022-01802-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01802-5</ArticleId><ArticleId IdType="pmc">PMC9038516</ArticleId><ArticleId IdType="pubmed">35473640</ArticleId></ArticleIdList></Reference><Reference><Citation>Puhach O., Meyer B., Eckerle I. SARS-CoV-2 viral load and shedding kinetics. Nat. Rev. Microbiol. 2023;21:147–161. doi: 10.1038/s41579-022-00822-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00822-w</ArticleId><ArticleId IdType="pmc">PMC9716513</ArticleId><ArticleId IdType="pubmed">36460930</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh K., Tang C., Norton D., Manivannan L. Molecular determinants of plaque size as an indicator of dengue virus attenuation. Sci. Rep. 2016;6:26100. doi: 10.1038/srep26100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep26100</ArticleId><ArticleId IdType="pmc">PMC4868997</ArticleId><ArticleId IdType="pubmed">27185466</ArticleId></ArticleIdList></Reference><Reference><Citation>Pyke A.T., Nair N., van den Hurk A.F., Burtonclay P., Nguyen S., Barcelon J., Kistler C., Schlebusch S., McMahon J., Moore F. Replication kinetics of B.1.351 and B.1.1.7 SARS-CoV-2 variants of concern including assessment of a B.1.1.7 mutant carrying a defective ORF7a gene. Viruses. 2021;13:1087. doi: 10.3390/v13061087.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13061087</ArticleId><ArticleId IdType="pmc">PMC8227137</ArticleId><ArticleId IdType="pubmed">34200386</ArticleId></ArticleIdList></Reference><Reference><Citation>Prince T., Dong X., Penrice-Randal R., Randle N., Hartley C., Goldswain H., Jones B., Semple M.G., Baillie J.K., Openshaw P.J.M., et al. Analysis of SARS-CoV-2 in Nasopharyngeal Samples from Patients with COVID-19 Illustrates Population Variation and Diverse Phenotypes, Placing the Growth Properties of Variants of Concern in Context with Other Lineages. mSphere. 2022;7:e0091321. doi: 10.1128/msphere.00913-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/msphere.00913-21</ArticleId><ArticleId IdType="pmc">PMC9241508</ArticleId><ArticleId IdType="pubmed">35491827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong G.U., Yoon G.Y., Moon H.W., Lee W., Hwang I., Kim H., Kim K.-D., Kim C., Ahn D.-G., Kim B.-T., et al. Comparison of plaque size, thermal stability, and replication rate among SARS-CoV-2 variants of concern. Viruses. 2022;14:55. doi: 10.3390/v14010055.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14010055</ArticleId><ArticleId IdType="pmc">PMC8781966</ArticleId><ArticleId IdType="pubmed">35062259</ArticleId></ArticleIdList></Reference><Reference><Citation>Guruprasad K. Mutations in human SARS-CoV-2 spike proteins, potential drug binding and epitope sites for COVID-19 therapeutics development. Curr. Res. Struct. Biol. 2022;4:41–50. doi: 10.1016/j.crstbi.2022.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crstbi.2022.01.002</ArticleId><ArticleId IdType="pmc">PMC8824715</ArticleId><ArticleId IdType="pubmed">35156058</ArticleId></ArticleIdList></Reference><Reference><Citation>Alizon S., Sofonea M.T. The evolution of SARS-CoV-2: Insights from virulence and transmission dynamics. J. Evol. Biol. 2021;34:1867–1880. doi: 10.1111/jeb.13896.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jeb.13896</ArticleId><ArticleId IdType="pmc">PMC8447366</ArticleId><ArticleId IdType="pubmed">34196431</ArticleId></ArticleIdList></Reference><Reference><Citation>Markov P.V., Ghafari M., Beer M., Lythgoe K., Simmonds P., Stilianakis N.I., Katzourakis A. The evolution of SARS-CoV-2. Nat. Rev. Microbiol. 2023;21:361–379. doi: 10.1038/s41579-023-00878-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-023-00878-2</ArticleId><ArticleId IdType="pubmed">37020110</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y., Liu J., Plante K.S., Plante J.A., Xie X., Zhang X., Ku Z., An Z., Scharton D., Schindewolf C., et al. The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. Nature. 2022;602:294–299. doi: 10.1038/s41586-021-04245-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-04245-0</ArticleId><ArticleId IdType="pmc">PMC8900207</ArticleId><ArticleId IdType="pubmed">34818667</ArticleId></ArticleIdList></Reference><Reference><Citation>Lista M.J., Winstone H., Wilson H.D., Dyer A., Pickering S., Galao R.P., De Lorenzo G., Cowton V.M., Furnon W., Suarez N., et al. The P681H mutation in the spike glycoprotein of the Alpha variant of SARS-CoV-2 escapes IFITM restriction and is necessary for type I interferon resistance. J. Virol. 2022;96:e0125022. doi: 10.1128/jvi.01250-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.01250-22</ArticleId><ArticleId IdType="pmc">PMC9749455</ArticleId><ArticleId IdType="pubmed">36350154</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanneti N.S., Patel A.K., Tan L.H., Marques A.D., Perera R.A.P.M., Sherrill-Mix S., Kelly B.J., Renner D.M., Collman R.G., Rodino K., et al. Comparison of SARS-CoV-2 variants of concern in primary human nasal cultures demonstrates Delta as most cytopathic and Omicron as fastest replicating. mBio. 2024;15:e0312923. doi: 10.1128/mbio.03129-23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03129-23</ArticleId><ArticleId IdType="pmc">PMC11005367</ArticleId><ArticleId IdType="pubmed">38477472</ArticleId></ArticleIdList></Reference><Reference><Citation>Davies N.G., Abbott S., Barnard R.C., Jarvis C.I., Kucharski A.J., Munday J.D., Pearson C.A.B., Russell T.W., Tully D.C., Washburne A.D., et al. Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England. Science. 2021;372:eabg3055. doi: 10.1126/science.abg3055.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abg3055</ArticleId><ArticleId IdType="pmc">PMC8128288</ArticleId><ArticleId IdType="pubmed">33658326</ArticleId></ArticleIdList></Reference><Reference><Citation>Samieefar N., Rashedi R., Akhlaghdoust M., Mashhadi M., Darzi P., Rezaei N. Delta Variant: The New Challenge of COVID-19 Pandemic, an Overview of Epidemiological, Clinical, and Immune Characteristics. Acta Bio-Medica Atenei Parm. 2022;93:e2022179. doi: 10.23750/abm.v93i1.12210.</Citation><ArticleIdList><ArticleId IdType="doi">10.23750/abm.v93i1.12210</ArticleId><ArticleId IdType="pmc">PMC8972886</ArticleId><ArticleId IdType="pubmed">35315394</ArticleId></ArticleIdList></Reference><Reference><Citation>Shuai H., Chan J.F.-W., Hu B., Chai Y., Yuen T.T.-T., Yin F., Huang X., Yoon C., Hu J.-C., Liu H., et al. Attenuated replication and pathogenicity of SARS-CoV-2 B.1.1.529 Omicron. Nature. 2022;603:693–699. doi: 10.1038/s41586-022-04442-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04442-5</ArticleId><ArticleId IdType="pubmed">35062016</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao H., Lu L., Peng Z., Chen L.L., Meng X., Zhang C., Ip J.D., Chan W.M., Chu A.W., Chan K.H., et al. SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells. Emerg. Microbes Infect. 2022;11:277–283. doi: 10.1080/22221751.2021.2023329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2021.2023329</ArticleId><ArticleId IdType="pmc">PMC8774049</ArticleId><ArticleId IdType="pubmed">34951565</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D., Rothenburger T., Ciesek S., Wass M.N., Michaelis M., Cinatl J. SARS-CoV-2 Omicron variant virus isolates are highly sensitive to interferon treatment. Cell Discov. 2022;8:42. doi: 10.1038/s41421-022-00408-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41421-022-00408-z</ArticleId><ArticleId IdType="pmc">PMC9087166</ArticleId><ArticleId IdType="pubmed">35538050</ArticleId></ArticleIdList></Reference><Reference><Citation>Meng B., Abdullahi A., Ferreira I.A.T.M., Goonawardane N., Saito A., Kimura I., Yamasoba D., Gerber P.P., Fatihi S., Rathore S., et al. Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and fusogenicity. Nature. 2022;603:706–714. doi: 10.1038/s41586-022-04474-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04474-x</ArticleId><ArticleId IdType="pmc">PMC8942856</ArticleId><ArticleId IdType="pubmed">35104837</ArticleId></ArticleIdList></Reference><Reference><Citation>Motozono C., Toyoda M., Zahradnik J., Saito A., Nasser H., Tan T.S., Ngare I., Kimura I., Uriu K., Kosugi Y., et al. SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity. Cell Host Microbe. 2021;29:1124–1136.e11. doi: 10.1016/j.chom.2021.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.06.006</ArticleId><ArticleId IdType="pmc">PMC8205251</ArticleId><ArticleId IdType="pubmed">34171266</ArticleId></ArticleIdList></Reference><Reference><Citation>Qu P., Evans J.P., Kurhade C., Zeng C., Zheng Y.-M., Xu K., Shi P.-Y., Xie X., Liu S.-L. Determinants and mechanisms of the low fusogenicity and high dependence on endosomal entry of Omicron subvariants. mBio. 2023;14:e03176-22. doi: 10.1128/mbio.03176-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03176-22</ArticleId><ArticleId IdType="pmc">PMC9972997</ArticleId><ArticleId IdType="pubmed">36625591</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun C., Wang H., Yang J., Kong D., Chen Y., Wang H., Sun L., Lu J., Teng M., Xie L. Mutation N856K in spike reduces fusogenicity and infectivity of Omicron BA.1. Signal Transduct. Target. Ther. 2023;8:75. doi: 10.1038/s41392-022-01281-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01281-8</ArticleId><ArticleId IdType="pmc">PMC9944258</ArticleId><ArticleId IdType="pubmed">36810728</ArticleId></ArticleIdList></Reference><Reference><Citation>Park S.B., Khan M., Chiliveri S.C., Hu X., Irvin P., Leek M., Grieshaber A., Hu Z., Jang E.S., Bax A., et al. SARS-CoV-2 Omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype. Commun. Biol. 2023;6:556. doi: 10.1038/s42003-023-04923-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42003-023-04923-x</ArticleId><ArticleId IdType="pmc">PMC10206564</ArticleId><ArticleId IdType="pubmed">37225764</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch J., Uckeley Z.M., Doldan P., Stanifer M., Boulant S., Lozach P.Y. TMPRSS2 expression dictates the entry route used by SARS-CoV-2 to infect host cells. EMBO J. 2021;40:e107821. doi: 10.15252/embj.2021107821.</Citation><ArticleIdList><ArticleId IdType="doi">10.15252/embj.2021107821</ArticleId><ArticleId IdType="pmc">PMC8365257</ArticleId><ArticleId IdType="pubmed">34159616</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiewsakun P., Phumiphanjarphak W., Ludowyke N., Purwono P.B., Manopwisedjaroen S., Srisaowakarn C., Ekronarongchai S., Suksatu A., Yuvaniyama J., Thitithanyanont A. Systematic exploration of SARS-CoV-2 adaptation to Vero E6, Vero E6/TMPRSS2, and Calu-3 cells. Genome Biol. Evol. 2023;15:evad035. doi: 10.1093/gbe/evad035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gbe/evad035</ArticleId><ArticleId IdType="pmc">PMC10078795</ArticleId><ArticleId IdType="pubmed">36852863</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M.N., Lokugamage K.G., Plante J.A., Scharton D., Bailey A.O., Sotcheff S., Swetnam D.M., Johnson B.A., Schindewolf C., Alvarado R.E., et al. QTQTN motif upstream of the furin-cleavage site plays a key role in SARS-CoV-2 infection and pathogenesis. Proc. Natl. Acad. Sci. USA. 2022;119:e2205690119. doi: 10.1073/pnas.2205690119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2205690119</ArticleId><ArticleId IdType="pmc">PMC9371735</ArticleId><ArticleId IdType="pubmed">35881779</ArticleId></ArticleIdList></Reference><Reference><Citation>Romeu A.R. Probable human origin of the SARS-CoV-2 polybasic furin cleavage motif. BMC Genom. Data. 2023;24:71. doi: 10.1186/s12863-023-01169-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12863-023-01169-8</ArticleId><ArticleId IdType="pmc">PMC10664542</ArticleId><ArticleId IdType="pubmed">37990144</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z., Zheng H., Lin H., Li M., Yuan R., Peng J., Xiong Q., Sun J., Li B., Wu J., et al. Identification of common deletions in the spike protein of severe acute respiratory syndrome coronavirus 2. J. Virol. 2020;94:e00790-20. doi: 10.1128/JVI.00790-20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00790-20</ArticleId><ArticleId IdType="pmc">PMC7431800</ArticleId><ArticleId IdType="pubmed">32571797</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson A.D., Williamson M.K., Lewis S., Shoemark D., Carroll M.W., Heesom K.J., Zambon M., Ellis J., Lewis P.A., Hiscox J.A., et al. Characterisation of the transcriptome and proteome of SARS-CoV-2 reveals a cell passage induced in-frame deletion of the furin-like cleavage site from the spike glycoprotein. Genome Med. 2020;12:68. doi: 10.1186/s13073-020-00763-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13073-020-00763-0</ArticleId><ArticleId IdType="pmc">PMC7386171</ArticleId><ArticleId IdType="pubmed">32723359</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>